Connecta Therapeutics
Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.
€3.1MClinical development financing
ParticipantCI
CDTI Innvierte
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $7.4M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionMOA Foodtech
MOA Foodtech uses AI-guided fermentation to turn agricultural and food-processing byproducts into functional protein and ingredient products for food and pet-food manufacturers. Its models help select suitable microorganisms and process conditions for each feedstock; the company also offers custom development and modular systems for valorising starch-rich side streams.
€3.3M€3.3 million financing round
Participant